Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension

Journal of Human Hypertension

Volumn 25, Issue 5, 2011, Pages 334-339

  Kurata, M ^a   Okura, T ^a   Irita, J ^a   Enomoto, D ^a   Nagao, T ^a   Jotoku, M ^a   Miyoshi, K ^a   Desilva, V R ^a   Higaki, J ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II receptor blocker; C reactive protein; essential hypertension; inflammation; osteopontin

Indexed keywords

AMLODIPINE; C REACTIVE PROTEIN; OSTEOPONTIN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOPONTIN; TETRAZOLES; VALINE;

EID: 79954761287     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.73     Document Type: Article

References (32)

1. Junaid A, Amara FM. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004; 44: 136-146. (Pubitemid 38296973)
2. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-224. (Pubitemid 24029153)
3. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta sub integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res 1995; 77: 665-672.
4. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713-724.
5. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-20962. (Pubitemid 30481782)
6. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin\a molecule for all seasons. QJM 2002; 95: 3-13.
7. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003; 92: 111-118. (Pubitemid 36105614)
8. Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: func-tional properties and transcriptional regulation by aldosterone. Hypertension 2008; 51: 507-513. (Pubitemid 351156440)
9. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112: 1318-1331. (Pubitemid 38057686)
10. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006; 27: 802-807.
11. Kurata M, Okura T, Watanabe S, Fukuoka T, Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci 2006; 111: 319-324. (Pubitemid 44690190)
12. Naito M, Shenoy A, Aoyama I, Koopmeiners JS, Komers R, Schnaper HW et al. High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol 2009; 30: 99-111.
13. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclero-sis 2008; 198: 22-28. (Pubitemid 351406364)
14. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholester-ol diet. J Hypertens 2003; 21: 361-369. (Pubitemid 36269708)
15. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, Makino H et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008; 22: 703-708.
16. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46: 735-739. (Pubitemid 44378243)
17. Okura T, Watanabe S, Kurata M, Koresawa M, Irita J, Enomoto D et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens 2008; 30: 415-422. (Pubitemid 352009300)
18. Abe K, Nakashima H, Ishida M, Miho N, Sawano M, Soe NN et al. Angiotensin II-induced osteopontin expression in vascular smooth muscle cells involves Gq/11, Ras, ERK, Src and Ets-1. Hypertens Res 2008; 31: 987-998. (Pubitemid 351895043)
19. Kramer AB, van der Meulen EF, Hamming I, van Goor H, Navis G Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71: 417-424.
20. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444.
21. Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010 (in press).
22. Tanaka N, Momiyama Y, Ohmori R, Yonemura A, Ayaori M, Ogura M et al. Effect of atorvastatin on plasma osteopontin levels in patients with hypercho-lesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: e129-e130. (Pubitemid 44305353)
23. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA et al. C-reactive protein induces matrix metalloproteinase-1 and-10 in human endothelial cells: implications for clinical and subclinical athero-sclerosis. J Am Coll Cardiol 2006; 47: 1369-1378.
24. Kurokawa M, Konno S, Matsukura S, Kawaguchi M, Ieki K, Suzuki S et al. Effects of corticosteroids on osteopon-tin expression in a murine model of allergic asthma. Int Arch Allergy Immunol 2009; 149(Suppl 1): 7-13.
25. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in a Japanese population with hypertension and other cardiovascu-lar disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439. (Pubitemid 46635780)
26. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. EurHeart J 2009; 30: 2461-2469.
27. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells. Diabetes 2001; 50: 1482-1490. (Pubitemid 32500183)
28. Wang X, Louden C, Ohlstein EH, Stadel JM, Gu J-L, Yue T-L. Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterios¬cler Thromb Vasc Biol 1996; 16: 1365-1372. (Pubitemid 26378227)
29. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-1696. (Pubitemid 23304531)
30. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kränzlin B et al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002; 16: 1850-1852.
31. Cecilia M, Giachelli SMS, Liaw L. Molecular and cellular biology of osteopontin potential role in cardiovascular disease. Trends Cardiovasc Med 1995; 5: 88-95.
32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.